截至收盘，上证指数收报4023.42点，上涨1.38%，深证成指收报13828.63点，上涨2.24%，创业板指收报3294.55点，上涨2.85%，北证 50指数上涨1.8%。A股市场合计成交25674.1亿元，较上一交易日增加5015.79亿元。 1.A股市场全天主力资金净流出62.98亿元 今日A股市场主力资金开盘净流出54.18亿元，尾盘净流入17.34亿元，A股市场全天主力资金净流出62.98亿元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 人得免權中 露多人候免 | | 尾盘净流入 超大单净买入 | | 2026-1-5 | -62.98 | -54. 18 | 17. 34 | 90. 80 | | 2025-12-31 | -270. 79 | -129.42 | -36. 63 | -63.89 | | 2025-12-30 | -238.28 | -116. 17 | -40. 17 | -94. 18 | | 2025-12-29 | -482.76 | -221.26 | -77.9 ...

Core Viewpoint - The biopharmaceutical industry in China experienced a volatile year in 2025, with significant growth in the first half followed by a sharp decline in the latter half, indicating a restructuring of the underlying logic of the industry [1][2][28]. Group 1: Industry Performance - The innovative drug sector saw explosive growth in the first half of 2025, with the China Innovation Drug Index rising by 13.43% and the Hong Kong Innovation Drug Index increasing by 60% [1][27]. - By December 28, 2025, the Hong Kong Innovation Drug Index had dropped over 20% since September, with many unprofitable biotech companies experiencing declines of over 40% [1][27]. Group 2: Policy Support - In 2025, the policy environment for biopharmaceuticals in China evolved to integrate national and local support, creating a comprehensive system for innovative drug development [4][30]. - Key policy initiatives included the release of measures to support innovative drug development, focusing on research support, inclusion in insurance, and clinical application [4][30]. - The introduction of a 30-day expedited review process for innovative drug clinical trial applications was implemented to enhance efficiency [4][30]. Group 3: Technological Advancements - The integration of AI in drug development accelerated in 2025, with AI tools becoming standard in pharmaceutical research and development [14][39]. - AI-driven companies like Insilico Medicine achieved significant milestones, including the rapid progression of drug candidates through clinical trials [14][40]. Group 4: Payment System Changes - The payment landscape for innovative drugs shifted from a focus on the lowest price to a more balanced approach that considers quality and reasonable pricing [16][42]. - The introduction of a commercial health insurance directory for innovative drugs marked a significant development, allowing for better access and affordability for patients [19][45]. Group 5: Business Development Transactions - The business development (BD) landscape in the innovative drug sector transitioned from a phase of enthusiasm to a more rational evaluation of value [22][48]. - By the end of 2025, the total amount of overseas licensing agreements in China's innovative drug sector exceeded $130 billion, setting a historical record [50]. - However, market reactions to BD announcements became more subdued, with significant stock price declines following major deals, indicating a reassessment of the quality and sustainability of such transactions [50][51].

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, which will be conducted shortly [1] Group 1 - The clinical trials will focus on the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for the treatment of PSMA-positive prostate cancer [1] - The trials will be open-label, multicenter, and will be conducted in phases Ib/II [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trial notifications regarding HRS9531 injection and HRS-5817 injection, allowing for clinical trials in adult patients with obesity or overweight using HRS9531 in combination with HRS-5817 [1] Group 1 - The company has received approval for clinical trials of HRS9531 injection [1] - The clinical trials will focus on adult patients who are obese or overweight [1] - The trials will involve the combination treatment of HRS9531 injection and HRS-5817 injection [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection and HRS-5817 injection [1] Group 1 - The approval includes conducting clinical trials of HRS9531 injection in combination with HRS-5817 injection for adult patients who are obese or overweight [1]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, indicating progress in its drug development pipeline for prostate cancer treatment [1] Group 1 - The company and its subsidiaries, Chengdu Shengdi Pharmaceutical Co., Ltd. and Tianjin Heng Rui Medicine Co., Ltd., will conduct clinical trials for HRS-4357 and HRS-5041 [1] - The clinical study will focus on the safety, tolerability, and preliminary efficacy of HRS-4357 in combination with HRS-5041 for treating PSMA-positive prostate cancer [1] - The trials are categorized as open-label, multi-center, and will be conducted in phases Ib/II [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, marking a significant step in the development of innovative cancer treatments [1] Group 1: Product Development - HRS-4357 injection is a first-class radioactive therapy drug developed by the company, which will now undergo clinical trials for a new indication in combination with HRS-5041 for treating prostate cancer patients who are positive for prostate-specific membrane antigen (PSMA) [1] - HRS-5041 is a novel, efficient, and selective ARPROTAC small molecule developed by the company, aimed at treating prostate cancer [1] - There are currently no similar products approved for marketing in both domestic and international markets, indicating a unique position for the company's offerings [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-002 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司福建盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 HRS9531 注射液、HRS-5817 注射液的《药物临床试验批准通知书》，将于近期开 展临床试验。现将相关情况公告如下： HRS9531 注射液是以 HRS9531 为主要活性成分，具有全球自主知识产权的新 型靶向胰高血糖素样肽-1 受体（GLP-1R）和葡萄糖依赖性促胰岛素肽受体（GIPR） 的双激动剂，可在体内调节糖脂代谢、抑制食欲和增强胰岛素敏感性，从而起到 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 药物名称 | HRS9531 注射液 HRS-5817 注射液 | | --- | --- | | 剂型 | 注射剂 | | 事项 | 临床试验 | | 受理号 | CXHL2501098、CXHL2501100、 CXHL250110 ...

HRS-5041 是公司开发的新型、高效、选择性的 AR PROTAC（雄激素受体-蛋 白降解靶向嵌合体）小分子，拟用于治疗前列腺癌。HRS-5041 对野生型及绝大 多数突变体的 AR 蛋白有显著的降解作用，与二代 AR 抑制剂相比，有克服耐药的 潜力。经查询，目前国内外暂无同类产品获批上市。截至目前，HRS-5041 片相 关项目累计研发投入约 9,266 万元。 三、风险提示 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将 按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行信息披 露义务。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-003 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...